Company Overview

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a global medical technology company. The company designs, manufactures, and markets orthopedic reconstructive implants, surgical equipment, and related products for orthopedic surgery. Through strategic acquisitions, notably Centerpulse in 2003 and Biomet in 2015, Zimmer Biomet has secured leading market shares in the reconstructive market across the United States, Europe, and Japan.

Business Operations and Products

Zimmer Biomet's extensive product portfolio includes orthopedic reconstructive products (such as knee and hip implants), S.E.T. products (encompassing sports medicine, biologics, foot and ankle, extremities, and trauma solutions), and craniomaxillofacial and thoracic products (for face, skull, and chest reconstruction/stabilization). The company also provides advanced technology, bone cement, and surgical instruments. These products are utilized to treat a wide range of bone, joint, and soft tissue disorders or injuries. Large joint implants account for approximately two-thirds of total revenue, with extremities, trauma, sports medicine, and related surgical products contributing another fourth.

Geographic Presence and Market Structure

The company's operations are structured across key segments: Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific. Zimmer Biomet serves a diverse customer base including orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, leveraging multiple healthcare channels globally.

Financial Performance

2024 Full Year Results

- Revenue: $7.68 billion (an increase of 3.85% year-over-year)

- Earnings: $903.80 million (a decrease of -11.74% year-over-year)

Q1 2025 Results

- Net Sales: $1.909 billion (an increase of 1.1% year-over-year; 2.3% on a constant currency basis)

- Diluted Earnings Per Share (EPS): $0.91

- Adjusted Diluted EPS: $1.81

Q2 2025 Results

- Net Sales: $2.077 billion (an increase of 7.0% year-over-year; 5.4% on a constant currency basis; 2.8% on an organic constant currency basis)

- Diluted EPS: $0.77

- Adjusted Diluted EPS: $2.07 (an increase of 3.0%)

Key Growth Drivers:

- Robust growth in U.S. Hips (5.2%) and Knees portfolios.

- Significant S.E.T. business growth of 17.3%.

Strategic Initiatives and Technology Advancement

Robotics and Innovation

Zimmer Biomet is actively capitalizing on the normalization of procedure volumes and the strategic placement of its Rosa robot. This initiative aims to drive higher-margin implant pull-through by integrating advanced robotic systems into hospitals and ambulatory surgical centers.

Recent Acquisitions

- The company has entered a definitive agreement to acquire Monogram Technologies for approximately $177 million upfront, with potential for additional milestone-based payments. This acquisition is set to position Zimmer Biomet as a leader in fully autonomous surgical robotics in orthopedics.

- Zimmer Biomet has completed the acquisition of Paragon 28, Inc., a specialized medical device company focused on the foot and ankle segment, significantly strengthening its presence in this high-growth area.

Strategic Partnerships

- Announced a strategic acquisition of Monogram Technologies to enhance robotics capabilities.

- Formed a partnership with Getinge for the distribution of Operating Room products.

2025 Guidance and Outlook

Zimmer Biomet has raised its full-year 2025 guidance, now projecting:

- Revenue Growth: 6.7-7.7% (reported)

- Adjusted EPS: $8.10-$8.30 (revised upwards from $7.90-$8.10)

Market Position and Competitive Advantages

Zimmer Biomet is a dominant force in large-joint reconstruction. The company anticipates sustained demand for large-joint replacements, driven by the aging baby boomer population and advancements in technology suitable for younger patients, which is expected to offset any price declines. With a market capitalization of $20.65 billion, Zimmer Biomet maintains a strong market position, supported by recent positive financial results and analyst ratings.

Corporate Leadership and Dividend Policy

Zimmer Biomet Holdings (NYSE: ZBH) has declared a quarterly cash dividend of $0.24 per share for Q2 2025, payable to stockholders of record as of June 26, 2025.

In 2022, the company strategically spun out its dental and spine businesses. This allowed Zimmer Biomet to sharpen its focus on its core orthopedic business and reinforce its market leadership in medical technology.

The company continues to fortify its market standing through strategic acquisitions, advancements in robotics, and a dedicated focus on high-growth segments like foot and ankle orthopedics. Its strong performance in Q2 2025 and upwardly revised full-year guidance underscore its commitment to delivering innovative orthopedic solutions while consistently rewarding shareholders through its dividend program.